Free tool
FAERS Monitor: Inflectra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125544 or its brand name (Inflectra, Infliximab-Dyyb). Reports on generic versions are filed under their own applications.
Reports
29,668
Serious
24,848
84% of reports
Hospitalization
7,353
Death reported
722
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use15,555
- condition aggravated10,827
- intentional product use issue8,399
- inappropriate schedule of product administration7,041
- arthralgia5,039
- drug ineffective3,658
- fatigue3,494
- weight increased3,200
- weight decreased3,079
- malaise2,963
- headache2,464
- nausea2,417
- blood pressure increased2,396
- covid-192,372
- pain2,356
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 7 |
| 2016 | 168 |
| 2017 | 1,138 |
| 2018 | 2,497 |
| 2019 | 1,612 |
| 2020 | 2,604 |
| 2021 | 3,484 |
| 2022 | 4,878 |
| 2023 | 4,251 |
| 2024 | 4,072 |
| 2025 | 2,706 |
| 2026 | 2,251 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,024,491 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional product use issueSignal | 8,399 | 75.1 | 73.6 | 557,248 |
| inappropriate schedule of product administrationSignal | 7,041 | 28.8 | 28.2 | 182,985 |
| condition aggravatedSignal | 10,827 | 26.1 | 25.7 | 256,150 |
| off label useSignal | 15,555 | 12.8 | 12.7 | 173,467 |
| blood pressure increasedSignal | 2,396 | 11.3 | 10.8 | 22,226 |
| weight increasedSignal | 3,200 | 10.3 | 9.9 | 26,645 |
| covid-19Signal | 2,372 | 9.7 | 9.3 | 18,409 |
| arthralgiaSignal | 5,039 | 8.7 | 8.5 | 34,525 |
| weight decreasedSignal | 3,079 | 7.9 | 7.6 | 18,577 |
| malaiseSignal | 2,963 | 4.8 | 4.7 | 9,082 |
| fatigueSignal | 3,494 | 3.2 | 3.1 | 5,433 |
| headacheSignal | 2,464 | 2.8 | 2.7 | 2,911 |
| painSignal | 2,356 | 2.7 | 2.6 | 2,640 |
| nauseaSignal | 2,417 | 2.2 | 2.1 | 1,575 |
| drug ineffective | 3,658 | 2.0 | 1.9 | 1,859 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.